GPL Announces Appointment of Alessandro Riva as CEO of its New Innovation Company General Announcement Filing viewer · member access Original SGX announcement
GPL Announces Presentation of New Subtype Analysis of GBR 830 General Announcement Filing viewer · member access Original SGX announcement
Outcome of the Board Meeting February 14, 2019 General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals enters into an Exclusive License Agreement with Grandpharma (China) Co Ltd General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL General Announcement Filing viewer · member access Original SGX announcement
BM Intimation to Consider & Approve Unaudited Financial Results for 3rd Qtr & 9 Months 31.12.2018 General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation General Announcement Filing viewer · member access Original SGX announcement
J. P. Morgan Healthcare Conference San Francisco USA Presentation General Announcement Filing viewer · member access Original SGX announcement
Update on Innovative R&D Capabilities and Pipeline Overview General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for Hydrocortisone Valerate Ointment USP, 0.2% General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05% General Announcement Filing viewer · member access Original SGX announcement
Half Yearly Results Financial Statements and Related Announcement Filing viewer · member access Original SGX announcement
GPL Announces Decision to Launch Phase 1 Trial in Solid Tumors General Announcement Filing viewer · member access Original SGX announcement
ANNOUNCEMENT OF RESULTS OF THE REPURCHASE AS AT THE EXPIRATION TIME General Announcement Filing viewer · member access Original SGX announcement
Intimation of proposed cash buyback in respect of Glenmark Pharmaceuticals Limited General Announcement Filing viewer · member access Original SGX announcement
Intimation of proposed cash buyback in respect of Glenmark of its USD 200 million General Announcement Filing viewer · member access Original SGX announcement
GPL receives ANDA approval for Estradiol Vaginal Inserts USP 10 mcg General Announcement Filing viewer · member access Original SGX announcement
GPL enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide General Announcement Filing viewer · member access Original SGX announcement
40th Annual General Meeting - September 28, 2018 General Announcement Filing viewer · member access Original SGX announcement
GPL Announces FDA Acceptance of the Companys First New Drug Application for Ryaltris General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for HAILEYTM General Announcement Filing viewer · member access Original SGX announcement
GPL approved the draft share purchase agreement to acquire 100 Per stake in Zorg Laboratories General Announcement Filing viewer · member access Original SGX announcement